Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet function and the bleeding time in progressive renal failure.

M P Gordge1, R W Faint, P B Rylance

  • 1Dept. of Renal Medicine, St. Philips Hospital, London, UK.

Thrombosis and Haemostasis
|August 30, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

More than shingles.

Clinical kidney journal·2018
Same author

Unusual abdominal masses.

Clinical kidney journal·2018
Same author

Tackling the 'brown' frown.

Clinical kidney journal·2018
Same author

Page kidney phenomenon secondary to an atypical presentation of Erdheim-Chester disease.

Clinical kidney journal·2015
Same author

Calciphylaxis.

Clinical kidney journal·2015
Same author

Cutaneous involvement in haemolytic uraemic syndrome.

Clinical kidney journal·2015
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
Same journal

Methylglyoxal Promotes RBC-Driven Procoagulant Activity and Venous Thrombosis under Diabetes-Relevant Conditions.

Thrombosis and haemostasis·2026
Same journal

Management of Inferior Vena Cava Thrombosis: Guidance from the Italian Society for the Study of Haemostasis and Thrombosis.

Thrombosis and haemostasis·2026
See all related articles

In progressive chronic renal failure (CRF), bleeding time is prolonged only in severe cases. Platelet function remains largely normal, suggesting other factors contribute to bleeding risk in CRF patients.

Area of Science:

  • Nephrology
  • Hematology
  • Clinical Pathology

Background:

  • Chronic renal failure (CRF) can affect hemostasis.
  • Understanding bleeding risk in CRF is crucial for patient management.

Purpose of the Study:

  • To investigate bleeding time and platelet function in patients with progressive chronic renal failure (CRF) of non-immunological origin.
  • To identify factors contributing to prolonged bleeding in CRF.

Main Methods:

  • Bleeding time and platelet function tests were conducted on 31 CRF patients and 22 healthy controls.
  • Patients were stratified into mild, moderate, and severe CRF based on plasma creatinine levels.
  • Assessed platelet aggregation, thromboxane generation, fibrinogen, C-reactive protein, and von Willebrand factor (vWF).

Related Experiment Videos

Main Results:

  • Bleeding time was significantly elevated only in severe CRF.
  • Haematocrit negatively correlated with bleeding time.
  • Platelet counts and aggregation responses were generally normal or increased.
  • Thromboxane production in clotting blood was reduced.
  • Plasma fibrinogen, C-reactive protein, and vWF levels increased with CRF severity.

Conclusions:

  • Prolonged bleeding time in progressive CRF is primarily associated with severe renal impairment.
  • Platelet aggregation and interaction with vWF do not appear to be the primary cause of prolonged bleeding time in CRF.
  • Reduced thromboxane production in clotting blood and elevated inflammatory markers may play a role in hemostatic alterations in CRF.